Transcription of EPP - 日本対がん協会
1 H23 010. RCU . 1.. 3 . - 23 7 18 5 .. - 1 23 8 5 10 .. - 2 23 9 30 25 .. 1) .. 18 22 .. (CDDP) (PEM) . (extrapleural pneumonectomy: EPP) . (feasibility study) . (JMRC-01 ) JMRC-01 . 42 22 11 . EPP (30/42) . (4/42) . feasibility . (17/42) .. / (pleurectomy/decortication: P/D) P/D . EPP . P/D . P/D EPP .. CDDP+PEM EPP . CDDP+PEM . P/D PEM . II P/D vs EPP .. P/D JMRC-01 .. EPP P/D II . P/D feasibility study .. (feasibility study) P/D .. 2) P/D . ( ) I-III (T1-3, N0-2, M0) . 75 PS(ECOG)0-1 CDDP (75mg/m2)+PEM (500mg/m2) . 3 P/D . PEM (500mg/m2) . P/D .. ( ) . 3) .. JMRC-01 17 .. 19 . 3.. JMRC-01 .. P/D . P/D feasibility . P/D vs EPP II . 4.. ( IRB) . ( IRB).. 5.. 1) Weder W, Nakano T, et al. The MARS feasibility trial: conclusions not supported by data. Lancet Oncol. 2011;12:1093-1094. 2) Maeda R, Nakano T, et al. Is serum thioredoxin-1 a useful clinical marker for malignant pleural mesothelioma? Antioxid Redox Signal, 5;685-689, 2011.
2 3) David Rice, Hasegawa S, Nakano T, et al. Recommendations for uniform definitions of surgical techniques for malignant pleural mesothelioma. A consensus report of the International Association for the Study of Lung Cancer International Staging Committee and the International Mesothelioma Interest Group. J Thorac Oncol, 6;1304 1312, 2011. 4) Yoshikawa Y, Fukuoka K, Tanaka F, Hasegawa S, Nakano T, et al. Frequent deletion of region carrying semaphorin 3G and aberrant expression of the genes participating in semaphorin signaling in the epithelioid type of malignant mesothelioma cells. Int J Oncol 2011; 39: 1365-74. 5) Yamada S, Fukuoka K, Nakano T, et al. Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma. Clin Chem Lab Med, 49;1721-1726, 2011. 6) Hirayama N, Fukuoka K, Nakano T. Pleural effusion VEGF levels as a prognostic factor of malignant pleural mesothelioma. Respir Med, 105;137-42, 2011. 7).
3 2011; 51:109-112. 8) , , , , , , , , . , , , , , , .. 2011; 66: 543-552. 9) , , , , , .. 2011; 66: 553-557. 10) , , , , , , , , .. 2011;. 66: 558-561. 11) . trimodality therapy. 2011; 7: 578-584.. RCU . RCU.
